Silence Therapeutics PLC ADR Annual stock financials by MarketWatch. View the latest SLN financial statements, income statements and financial ratios.
A recent prospective study sought to identify the subgroup of melanoma patients (based on age and tumor thickness) in which the risk of nodal metastasis is low and who may avoid routine SLN biopsy.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback